[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100663303":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":38,"studyPopulation":27,"armGroups":39,"interventions":65,"overallOfficials":119,"centralContacts":123,"locations":129,"responsibleParty":145,"collaborators":147,"id":153,"slug":154,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":27,"eligibilityCriteria":159,"healthyVolunteers":155,"sex":160,"minAge":27,"maxAge":161,"enrollmentInfo":162,"targetDuration":27,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":184,"whyStopped":27,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":27},[9,13],{"measure":10,"description":11,"timeFrame":12},"Rate of Complete Tumor Response (CTR) among patients in Strata A, B, and C","The proportion of patients whose extent of tumor resection meets criteria for gross total \u002F near total resection (GTR\u002FNTR) after neoadjuvant therapy and surgery.","approximately 4 months after enrollment",{"measure":14,"description":15,"timeFrame":16},"Rate of safe surgical resection among patients in Strata A, B, and C","Proportion of patients whose surgery is completed without clinically significant intra-operative blood loss\u002Fhemorrhage. Success for this outcome measure will include surgery without any of the following:\n\n(i) Initiation of massive transfusion protocol- i.e., requiring more than one volume (80ml\u002FKg) of transfusion over a period of 24 hours\n\n(ii) Hemorrhage leading to cessation of surgery\n\n(iii) Hemorrhagic complications leading to second neurosurgery within 72 hours of the first surgery.","Up to 72 hours after surgery",[18,22,25,29],{"measure":19,"description":20,"timeFrame":21},"Event free survival (EFS)","EFS is defined as time from enrollment for treatment (including bridge therapy) until progression, subsequent malignancy or death for any reason or until last follow-up, whichever is earlier.","2 years",{"measure":23,"description":24,"timeFrame":21},"Overall survival (OS)","OS is defined as time from enrollment for treatment (including bridge therapy) until death for any reason or until last follow-up, whichever is earlier.",{"measure":26,"description":27,"timeFrame":28},"Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: BSID-4",null,"Pre-surgery\u002Fbaseline and after the intervention\u002Fprocedure\u002Fprimary surgery for up to 12 weeks",{"measure":30,"description":27,"timeFrame":28},"Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: NIH Baby Toolbox",{"allocation":32,"interventionModel":33,"interventionModelDescription":34,"primaryPurpose":35,"observationalModel":27,"timePerspective":27,"maskingInfo":36},"NON_RANDOMIZED","PARALLEL","Open label neoadjuvant treatment, followed by primary surgery, followed by adjuvant therapy in 3 strata (strata A, B, C) with residual tumor and adjuvant therapy only in patients with no residual tumor (stratum D)","TREATMENT",{"masking":37,"maskingDescription":27,"whoMasked":27},"NONE","Primary Objective\n\n* To estimate the complete tumor response rate (CTR) associated with molecularly directed neoadjuvant treatment (entrectinib for NTRK1\u002F2\u002F3 and ROS1, alectinib for ALK, and chemotherapy for tumors with other fusions and no fusions). (Strata A, B, and C)\n* To estimate the safe surgical resection rate associated with molecular-directed neo-adjuvant treatment entrectinib for NTRK1\u002F2\u002F3 and ROS1, alectinib for ALK, and chemotherapy for tumors with other fusions and no fusions. (Strata A, B, and C)\n\nSecondary Objectives\n\n* To estimate the stratum-specific and study-wide event-free survival (EFS) and overall survival (OS) for patients enrolled in SJIHG25 (Strata A, B, C, and D)\n* To estimate the change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment. (Strata A, B, and C)\n\nThis is a phase II clinical trial evaluating the use of molecularly directed neoadjuvant treatment for patients with newly diagnosed Infant-Type Hemispheric Glioma (IHG) to improve surgical outcome (efficacy and safety).\n\nBridge Therapy is recommended for participants who are being screened (participants who have signed the screening consent) for the following reasons:\n\n* Participant can be enrolled on the stratum bridge and 1-4 courses of cytotoxic chemotherapy CCE (carboplatin IV day 2, cyclophosphamide IV day1, and etoposide IV days 1 and 2), which may be given prior to surgical intervention to stabilize the patient. Each cycle of CCE treatment cycle is approximately 28 days in length.\n* If the waiting period for diagnostic work-up is deemed unsafe for clinical reasons, the participant may enroll in the stratum bridge and receive one course of bridge chemotherapy with CCE before enrollment to stratum A, B, or C.\n* Where a molecular target has been identified prior to screening and confirmation of diagnosis by central pathology review, the participant can be enrolled on stratum bridge and started on treatment based on the molecular target (alectinib po day1-28, entrectinib po day1-28, or chemotherapy (CCE), with pending central pathology review, if waiting for completion of the central pathology review is deemed to put the patient at increased risk of tumor progression.\n\nDecisions regarding bridge therapy need to be discussed and approved by the study PI\u002Fteam before starting treatment.\n\nEnrollment in strata A, B, C, and D can occur only after central pathology review at St. Jude Children's Research Hospital confirms the diagnosis. Participants will be assigned to treatment strata based on whether residual tumor is present and types of RTK fusion.\n\nParticipants with ALK fusion will receive alectinib as neoadjuvant treatment (Stratum A), participants with NTRK 1\u002F2\u002F3 or ROS1 fusions will receive entrectinib as neoadjuvant treatment (Stratum B), and participants with no RTK fusion or RTK fusions other than ALK, ROS1 or NTRK1\u002F2\u002F3 (including MET fusion) will receive chemotherapy with carboplatin, etoposide, and cyclophosphamide as neoadjuvant treatment (Stratum C). Post primary surgery all participants on Strata A, B and C will be treated with 4 courses (1 course = 28 days) of adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide.\n\nThe participants who have no residual disease at the time of enrollment will be treated with 4 courses (1 course = 28 days) of adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide on stratum D.\n\nParticipants will be followed for five years following enrollment.",[40,52,57,61],{"label":41,"type":42,"description":43,"interventionNames":44},"Stratum A","EXPERIMENTAL","* Neoadjuvant Treatment: Participants with ALK fusions will receive neoadjuvant treatment (4 Courses) with alectinib.\n* Surgery\n* Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).",[45,46,47,48,49,50,51],"Drug: Alectinib","Procedure: Surgery","Drug: Cyclophosphamide","Drug: Etoposide","Drug: Carboplatin","Biological: Filgrastim","Biological: Pegfilgrastim",{"label":53,"type":42,"description":54,"interventionNames":55},"Stratum B","* Neoadjuvant Treatment: Participants with NTRK 1\u002F2\u002F3 or ROS1 fusions will receive neoadjuvant (4 Courses) treatment with entrectinib.\n* Surgery\n* Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).",[56,46,47,48,49,50,51],"Drug: Entrectinib",{"label":58,"type":42,"description":59,"interventionNames":60},"Stratum C","* Neoadjuvant Treatment: Participants no RTK fusion or RTK fusions other than ALK, ROS1 or NTRK1\u002F2\u002F3 (including MET fusion) will receive neoadjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).\n* Surgery\n* Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).",[47,48,49,51,46],{"label":62,"type":42,"description":63,"interventionNames":64},"Stratum D","Participants who have no measurable residual disease at the time of enrollment.\n\n* Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).",[47,48,49,50,51],[66,73,78,85,91,97,103,110,116],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"DRUG","Alectinib","By mouth, nasogastric, or gastronomy\u002Fstomach tube, Day 1-28",[41],[72],"RO5424802",{"type":67,"name":74,"description":69,"armGroupLabels":75,"otherNames":76},"Entrectinib",[53],[77],"RO7102122",{"type":79,"name":80,"description":81,"armGroupLabels":82,"otherNames":83},"PROCEDURE","Surgery","Primary surgery (Strata A, B, and C) post Neoadjuvant therapy with a goal of attaining gross total (GTR) or near total resection (NTR) of the tumor.",[41,53],[84],"Surgical Resection",{"type":67,"name":86,"description":87,"armGroupLabels":88,"otherNames":89},"Cyclophosphamide","IV (intravenous) day 1",[41,53,58,62],[90],"Cytoxan",{"type":67,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"Etoposide","IV (intravenous) days 1 and 2",[41,53,58,62],[96],"VP-16",{"type":67,"name":98,"description":99,"armGroupLabels":100,"otherNames":101},"Carboplatin","IV (intravenous) day 2",[41,53,58,62],[102],"Paraplatin",{"type":104,"name":105,"description":106,"armGroupLabels":107,"otherNames":108},"BIOLOGICAL","Filgrastim","Subcutaneous (under the skin) or IV (intravenous) day 3",[41,53,62],[109],"G-CSF",{"type":104,"name":111,"description":112,"armGroupLabels":113,"otherNames":114},"Pegfilgrastim","Subcutaneous (under the skin) day 3",[41,53,58,62],[115],"Neulasta",{"type":79,"name":80,"description":81,"armGroupLabels":117,"otherNames":118},[58],[84],[120],{"name":121,"affiliation":5,"role":122},"Aditi Bagchi, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[124],{"name":125,"role":126,"phone":127,"phoneExt":27,"email":128},"Tabatha E. Doyle, RN","CONTACT","901-595-2544","tabatha.doyle@stjude.org",[130],{"facility":5,"status":27,"city":131,"state":132,"zip":133,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":141,"contacts":142},"Memphis","Tennessee","38105","United States","US",{"type":137,"coordinates":138},"Point",[139,140],-90.04898,35.14953,{"lat":140,"lon":139},[143,144],{"name":125,"role":126,"phone":127,"phoneExt":27,"email":128},{"name":121,"role":122,"phone":27,"phoneExt":27,"email":27},{"type":146,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[148,150],{"name":149,"class":6},"St. Baldrick's Foundation",{"name":151,"class":152},"Genentech, Inc.","INDUSTRY","100663303","phase-2-molecularly-stratified-trial-for-newly-diagnosed-infant-type-hemispheric-glioma-100663303",false,"NCT07916389","Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma","A Molecularly Stratified Phase II Trial for Newly Diagnosed Infant-Type Hemispheric Glioma (IHG)","Inclusion Criteria: Screening\n\n* Patient with presumptive or suspected (new) diagnosis of Infant-Type Hemispheric Glioma (IHG)\n* Patient age at diagnosis is from birth to ≤ 60 months\n* Patient has MRI\u002FCT scan imaging of a supra-tentorial, hemispheric tumor avail-able for review before screening consent.\n* Patient is willing to undergo a biopsy procedure to confirm tissue diagnosis.\n* Adequate tumor tissue for central review of pathology, at the St. Jude Children's Research Hospital, DNA methylation array analysis, and NGS testing should be provided, if available from previous surgery, but is not required for screening eligibility.\n* The parent or legal guardian of the patient should be able to understand and be willing to sign a written informed consent document according to institutional guidelines\n\nInclusion Criteria: Enrollment\n\n* Without a central pathology confirmed diagnosis of IHG\n\n  * Stratum-Bridge\n\n    * The patient should meet all screening criteria and should have signed the screening consent.\n    * Meets one of the exception\u002Fmodification criteria\n* Centrally confirmed diagnosis of IHG\n\n  * Strata A and B\n\n    * The tumor has confirmed in-frame gene fusions involving ALK (Stratum A)\n    * The tumor has confirmed in-frame gene fusions involving NTRK1\u002F2\u002F3 or ROS1 (Stratum B).\n    * A measurable primary residual tumor at the time of enrollment\n  * Stratum C\n\n    * Central pathology review doesn't detect in-frame gene fusion involving ALK, NTRK 1\u002F2\u002F3, or ROS1in the tumor\n    * Central pathology review confirms the presence of in-frame MET gene fusion or any other in frame fusion other than those involving ALK, NTRK1\u002F2\u002F3, or ROS1 gene fusions\n    * A measurable primary residual tumor at the time of enrollment\n  * Stratum D\n\n    * No measurable primary residual tumor at the time of enrollment\n\nExclusion Criteria: (All Strata)\n\n* Age \\> 60 months\n* Any prior cancer-directed therapy\n* Organ Dysfunction, or a medical condition that, in the principal investigator's judgment, could compromise their ability to tolerate or absorb protocol therapy or would interfere with study procedures and results.","ALL","60 Months",{"count":163,"type":164},50,"ESTIMATED","INTERVENTIONAL",[167],"PHASE2","The purpose of this study is to test whether giving treatment before surgery helps babies who are newly diagnosed with Infant-Type Hemispheric Glioma (IHG) have safer and better surgery results.",[170],"Infant-Type Hemispheric Glioma",[172,170,173,174,175,176,177,178,179,180,181,182,80,183],"Brain Tumor","Newly Diagnosed","Molecularly Stratified","Gene fusions involving ALK","Gene fusions involving NTRK1\u002F2\u002F3","Gene fusions involving ROS1","In-frame MET gene fusion or any other in frame fusion","Measurable primary residual tumor","No measurable primary residual tumor","Supra-tentorial, hemispheric tumor","Neoadjuvant treatment","Adjuvant treatment","NOT_YET_RECRUITING","2026-10-29",{"date":187,"type":188},"2026-11-04","ACTUAL",{"date":190,"type":164},"2026-11",{"date":192,"type":164},"2036-11",{"name":5,"class":6},1]